Trial Profile

A Phase 2, Open-label, Single-arm, Proof-of-concept Study Evaluating the Efficacy and Safety of Belantamab Mafodotin Administered in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain Amyloidosis (ALANIS)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belantamab mafodotin (Primary) ; Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary)
Indications Amyloid light-chain amyloidosis
Focus Proof of concept; Therapeutic Use
Acronyms ALANIS
Sponsors GSK

16 Dec 2025 Planned End Date changed from 27 Oct 2031 to 4 Feb 2032.
16 Dec 2025 Planned primary completion date changed from 30 Apr 2027 to 10 Aug 2027.
16 Dec 2025 Planned initiation date changed from 1 Dec 2025 to 11 Mar 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com